Intel stock spikes after report of possible US government stake
Chief Accounting Officer of Aspen Aerogels (NYSE:ASPN), Daniel Santhosh P, sold 6,410 shares of common stock in two transactions on August 12 and 13, 2025, for approximately $47,317. The transactions come as the company, currently valued at $617.7 million, trades near its InvestingPro Fair Value, suggesting balanced market pricing.
On August 12, Daniel sold 4,410 shares, in multiple trades, with prices ranging from $7.31 to $7.32. Following this transaction, Daniel directly owns 19,879 shares. On August 13, Daniel sold 2,000 shares at a price of $7.54. Following the second transaction, Daniel directly owns 17,879 shares, represented as restricted stock units. The company maintains strong liquidity with a current ratio of 3.98, though its stock has experienced significant volatility, falling nearly 10% in the past week. Get deeper insights into ASPN’s financial health and access 11 additional ProTips with a comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, Aspen Aerogels reported its Q2 2025 earnings, surpassing revenue forecasts with a total of $78 million, compared to the expected $72.53 million. The company’s earnings per share (EPS) also exceeded expectations, reporting $0.04 against the anticipated -$0.09, marking a significant surprise. In addition to these earnings results, Barclays downgraded Aspen Aerogels from Equalweight to Underweight, citing concerns over reduced electric vehicle production at General Motors and the impact of the removal of the $7,500 consumer EV tax credit. Barclays also lowered its price target for Aspen Aerogels from $7.00 to $6.00. Meanwhile, Canaccord Genuity maintained a Buy rating on the stock but adjusted its price target from $11.00 to $10.00, attributing the change to "continued uncertainty." These developments highlight varying perspectives on Aspen Aerogels’ growth trajectory amidst a changing market landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.